The web-based survey is conducted in EU countries where Mayzent (siponimod) is available on the market and reimbursed for at least 6 months, to capture the knowledge and understanding of specific Mayzent safety measures by HCPs and patients/caregivers with access to Mayzent (siponimod).
Survey to be completed independently by HCPs (neurologists treating patients with MS and MS specialist nurses) and patients/caregivers.